Prevalence of adenomatous polyposis in a fecal immunochemical test-based colorectal cancer screening program and risk of advanced neoplasia during follow-up

Abstract

Background Current guidelines recommend genetic counseling and intensive colonoscopy surveillance for patients with ≥ 10 colorectal adenomas based on scarce data. We investigated the prevalence of this condition in a fecal immunochemical test (FIT)-based colorectal (CRC) screening program, and the incidence of metachronous lesions during follow-up.

Methods We retrospectively included all FIT-positive participants with ≥ 10 adenomas at index colonoscopy between 2010 and 2018. Surveillance colonoscopies were collected until 2019. Patients with inherited syndromes, serrated polyposis syndrome, total colectomy, or lacking surveillance data were excluded. The cumulative incidence of CRC and advanced neoplasia were analyzed by Kaplan–Meier analysis. Risk factors for metachronous advanced neoplasia were investigated by multivariable logistic regression analysis.

Results 215 of 9582 participants (2.2 %) had ≥ 10 adenomas. Germline genetic testing was performed in 92 % of patients with ≥ 20 adenomas, identifying two inherited syndromes (3.3 %). The 3-year cumulative incidence of CRC and advanced neoplasia were 1 % and 16 %, respectively. In 39 patients (24.2 %), no polyps were found on first surveillance colonoscopy. The presence of an advanced adenoma was independently associated with a higher risk of advanced neoplasia at first surveillance colonoscopy (odds ratio 3.91, 95 %CI 1.12–13.62; P = 0.03). Beyond the first surveillance colonoscopy, the risk of metachronous advanced neoplasia was lower.

Conclusions The prevalence of ≥ 10 adenomas in a FIT-based CRC screening program was 2.2 %; a small proportion of inherited syndromes were detected, even amongst those with ≥ 20 adenomas. A low rate of post-colonoscopy CRC was observed and the risk of advanced neoplasia beyond the first surveillance colonoscopy tended to progressively decrease throughout successive follow-ups.

^* Joint senior authors

Publication History

Received: 14 May 2021

Accepted after revision: 04 October 2021

Accepted Manuscript online:
04 October 2021

Article published online:
21 December 2021

• References

• 1 Syngal S, Brand RE, Church JM. et al. ACG Clinical Guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223-262
• 2 Grover S, Kastrinos F, Steyerberg EW. et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012; 308: 485-492
• 3 Rutter MD, East J, Rees CJ. et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut 2020; 69: 201-223
• 4 Gupta S, Lieberman D, Anderson JC. et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2020; 91: 463-485.e5
• 5 Hampel H, Bennett RL, Buchanan A. et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral indications for cancer predisposition assessment. Genet Med 2015; 17: 70-87
• 6 Stoffel EM, Mangu PB, Gruber SB. et al. Hereditary colorectal cancer syndromes: American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015; 33: 209-217
• 7 Monahan KJ, Bradshaw N, Dolwani S. et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut 2020; 69: 411-444
• 8 van Leerdam ME, Roos VH, van Hooft JE. et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2019; 51: 877-895
• 9 Hassan C, Antonelli G, Dumonceau J-M. et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy 2020; 52: 687-700
• 10 Kaminski MF, Robertson DJ, Senore C. et al. Optimizing the quality of colorectal cancer screening worldwide. Gastroenterology 2020; 158: 404-417
• 11 Castaneda D, Popov VB, Verheyen E. et al. New technologies improve adenoma detection rate, adenoma miss rate, and polyp detection rate: a systematic review and meta-analysis. Gastrointest Endosc 2018; 88: 209-222.e11
• 12 Rutter MD, Bretthauer M, Hassan C. et al. Principles for evaluation of surveillance after removal of colorectal polyps: Recommendations from the World Endoscopy Organization. Gastroenterology 2020; 158: 1529-1533.e4
• 13 Stanich PP, Pearlman R, Hinton A. et al. Prevalence of germline mutations in polyposis and colorectal cancer–associated genes in patients with multiple colorectal polyps. Clin Gastroenterol Hepatol 2019; 17: 2008-2015.e3
• 14 Cubiella J, Marzo-Castillejo M, Mascort-Roca JJ. et al. Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 update. Gastroenterol Hepatol 2018; 41: 585-596
• 15 Lee TJW, Nickerson C, Goddard AF. et al. Outcome of 12-month surveillance colonoscopy in high-risk patients in the national health service bowel cancer screening programme. Colorectal Dis 2013; 15: e435-e42
• 16 Dekker E, Bleijenberg A, Balaguer F. et al. Update on the World Health Organization criteria for diagnosis of serrated polyposis syndrome. Gastroenterology 2020; 158: 1520-1523
• 17 Kaminski MF, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
• 18 Rembacken B, Hassan C, Riemann JF. et al. Quality in screening colonoscopy: Position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957-968
• 19 Rubio CA, Nesi G, Messerini L. et al. The Vienna classification applied to colorectal adenomas. J Gastroenterol Hepatol 2006; 21: 1697-1703
• 20 Crockett SD, Nagtegaal ID. Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology 2019; 157: 949-966.e4
• 21 Rutter MD, Beintaris I, Valori R. et al. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology 2018; 155: 909-925.e3
• 22 Park SK, Hwang SW, Kim KO. et al. Risk of advanced colorectal neoplasm in patients with more than 10 adenomas on index colonoscopy: A Korean Association for the Study of Intestinal Diseases (KASID) study. J Gastroenterol Hepatol 2017; 32: 803-808
• 23 Click B, Pinsky PF, Hickey T. et al. Association of colonoscopy adenoma findings with long-term colorectal cancer incidence. JAMA 2018; 319: 2021-2031
• 24 Wieszczy P, Kaminski MF, Franczyk R. et al. Colorectal cancer incidence and mortality after removal of adenomas during screening colonoscopies. Gastroenterology 2020; 158: 875-883.e5
• 25 Atkin W, Wooldrage K, Brenner A. et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol 2017; 18: 823-834